The AAPM 2021 educational program will be available in fall 2020. In the meantime browse 2020 meeting sessions and speakers to get a sense of the premier pain education offered during the AAPM Annual Meeting & Preconferences. Access recordings of past meeting sessions on demand.

12:30-1:30 PM Thursday, February 27

Emerging Trends in Migraine Diagnosis and Treatment

Educational Objectives

After attending this symposium, participants should be better able to:

  • Explore the underlying biology that establishes migraine as a neurological disease
  • Understand the impact of migraine on patients’ daily lives
  • Understand how to diagnose and classify migraine


This presentation will discuss migraine diagnosis, classification and treatment as well as migraine-associated patient burden.

Activity sponsored by: Novartis

12:30-1:30 PM Friday, February 28

A Common Sense Approach to: Lawsuit Prevention, Tax Reduction & License Protection


Art McOmber
Barb McOmber
Natalia McOmber
Daniel McOmbie

Educational Objectives

After attending this symposium, participants should be better able to:

  • Keep their name and license off of the NPDB.
  • Eliminate costly legal fees associated with lawsuits.
  • Protect their earning power.
  • Utilize proven tax strategies.


Legally Mine is an asset protection and tax strategy group. The mission of Legally Mine is to empower members of the healthcare community with the knowledge and tools to protect their assets from lawsuits, build professional license safeguards into their legal structures and legitimately reduce their tax liability.

Activity Sponsored by: Legally Mine

7:00 AM–8:30 AM Friday, February 28

AAPM Foundation Spotlight: Opioid Reduction (102)

Members of a consensus committee formed to address the care of those on long-term, high-dose opioids, especially “legacy patients,” will discuss methods and ethics of compassionate management with extensive audience participation. Criteria for maintaining vs. weaning, opioid use “gray zones,” the role of buprenorphine, i.a., will be discussed.

This is a non-CME event.

AAPM Foundation Opioid Reduction Consensus Project Introduction

Charles Argoff, MD

High Dose Patients: Taper or Maintain?

Ajay Manhapra

What Should Be Done About Dangerous Combinations

Michael Hooten, MD

When Is Referral Actually Abandonment

Mark Sullivan

Continue or Curtail, Consensual or Coercive: Who Decides?

Ed Covington

How to Taper

Mark Sullivan

Complex Persistent Dependence

Jane Ballantyne, MD FRCA

Fiscal Responsibility Versus Duties as Healers

Steven Stanos, DO

A Balancing Act: Tools to Help Taper

Jennifer Murphy, PhD

Learning Objectives:

  • Determine whether and how to reduce opioids.
  • Develop and implement a plan for comfortable opioid and sedative reduction.
  • Effectively manage those who, despite no opioid use disorder, respond poorly to both opioid escalation and reduction.
12:45-1:45 PM Saturday, February 29

A Fresh Look at Atypical Opioids as Frontline Analgesics: Science NOT Misconceptions

Program Overview

Opioid analgesics are an important part of our therapeutic armamentarium, but can also have serious consequences. As the pendulum swings from liberal opioid prescribing to a more measured approach, clinicians must ensure it does not swing too far. All opioids are not the same and they vary in their potential for respiratory depression, the major cause of overdose death. Three atypical opioids—buprenorphine, tapentadol, and tramadol—are currently available. Unlike conventional opioids that primarily rely on mu-opioid receptor agonism for analgesia and adverse effects, atypical opioids have additional mechanisms of action that increase the separation between desired therapeutic and unwanted effects. In particular, several groups have identified buprenorphine as a preferred opioid for chronic pain because it has a ceiling to respiratory depression. However, buprenorphine’s complex pharmacology and development history, which includes treatment of opioid use disorder, have led to longstanding misconceptions that buprenorphine is a weaker older drug with limited utility. The faculty will address misconceptions about the pharmacology, analgesic efficacy, and safety of buprenorphine, and provide recommendations on the appropriate use of buprenorphine for chronic pain, including conversion strategies for switching from conventional opioids to buprenorphine.


Lynn R. Webster, MD
Vice President of Scientific Affairs, 
PRA Health Sciences
Salt Lake City, Utah

Richard L. Rauck, MD
President, Carolinas Pain Institute
Medical Director, Center for Clinical Research
Pain Fellowship Director,
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Learning Objectives

After completing this activity, participants should be better able to:

  • Describe the pharmacologic and safety differences between conventional and atypical opioids.
  • Identify appropriate patients who would benefit from buprenorphine as a first-line opioid analgesic.
  • Describe a strategy to transition opioid therapy from full mu-opioid analgesics to buprenorphine when appropriate.

Register now! There is no registration fee to attend this CME activity.

Supported by an educational grant from BioDelivery Sciences International, Inc.

Accreditation and Credit Designation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Center for Independent Healthcare Education (Center) and PharmaCom Group. Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Center designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME.

Nurse Practitioners
Nurse Practitioners will receive certificate of AMA PRA Category 1 Credit™ as this is an ACCME accredited program and its accreditation is recognized by Nurse Practitioner boards.

12:45 PM-1:45 PM Saturday, February 29

Opioid Induced Respiratory Depression – latest thinking – is safety within our reach?


Dr Martin Cheatle PhD. Director, Behavioral Medicine - Penn Pain Medicine Center. Associate Professor of Psychology in Psychiatry at the Hospital of the University of Pennsylvania
Dr Andrew Germanovich DO. Anesthesiologist, Orange County, Ca.

Educational Objectives

After attending this symposium, participants should be better able to:

  • Understand latest understanding of, and risks from, OIRD.
  • Understand who is at risk and how Physicians can minimize the issue.
  • Learn of latest thinking around how to prevent OIRD in the future.


Over 100 Americans die every day due to OIRD, yet it is not well understood by patients and some Physicians. This Symposium will take participants through the latest thinking and science, and define who is at risk in each segment of the population, from those with legitimate prescriptions, to those misusing Opioids. It will cover issues of concomitant medications and how they impact the risk profile, and will guide participants through the best ways to mitigate risk in a highly vulnerable population.

Activity sponsored by: Masimo


Martin, Cheatle, PhD

Andrew Germanovich DO

AJOVY® (fremanezumab-vfrm) Injection: An anti-CGRP for the Preventive Treatment of Migraine in Adults


Charles E. Argoff , MD, CPE
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Albany, NY

Educational Objectives

After attending this symposium, participants should be better able to:

  • Provide a review of migraine impact, diagnosis, and treatment guidelines
  • Review recent information on migraine pathophysiology and the role of CGRP in ­migraine
  • Discuss clinical trial study design and background on AJOVY as an anti-CGRP for the preventive treatment of migraine in adults
  • Review the efficacy, safety, and dosing/ administration of AJOVY in clinical trials


During this presentation, faculty will provide an overview of AJOVY® (fremanezumab-vfrm) injection as a preventive treatment of migraine in adults. The presentation will begin with a discussion of the migraine disease state, including migraine pathophysiology. This will be followed by a review of the efficacy and safety of AJOVY. Additionally, participants will have the opportunity to ask questions of the faculty.


Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Adverse Reactions: The most common adverse reactions (_5% and greater than placebo) were injection site reactions.

Activity sponsored by: Teva Pharmaceuticals

Subscribe to this RSS feed